title: Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.
abstract: Interleukin-6 (IL-6) triggers the formation of a high affinity receptor complex with the ligand binding subunit IL-6Ralpha and the signal transducing chain gp130. Since the intracytoplasmic region of the IL-6Ralpha does not contribute to signaling, soluble forms of the extracytoplasmic domain (sIL-6Ralpha), potentiate IL-6 bioactivity and induce a cytokine-responsive status in cells expressing gp130 only. This observation, together with the detection of high levels of circulating soluble human IL-6Ralpha (shIL-6Ralpha) in sera, suggests that the hIL-6-shIL-6Ralpha complex is an alternative form of the cytokine. Here we describe the generation of human IL-6 (hIL-6) variants with strongly enhanced shIL-6Ralpha binding activity and bioactivity. Homology modeling and site-directed mutagenesis of hIL-6 suggested that the binding interface for hIL-6Ralpha is constituted by the C-terminal portion of the D-helix and residues contained in the AB loop. Four libraries of hIL-6 mutants were generated by each time fully randomizing four different amino acids in the predicted AB loop. These libraries were displayed monovalently on filamentous phage surface and sorted separately for binding to immobilized shIL-6Ralpha. Mutants were selected which, when expressed as soluble proteins, showed a 10- to 40-fold improvement in shIL-6Ralpha binding; a further increase (up to 70-fold) was achieved by combining variants isolated from different libraries. Interestingly, high affinity hIL-6 variants show strongly enhanced bioactivity on cells expressing gp13O in the presence of shIL-6Ralpha at concentrations similar to those normally found in human sera.
authors.affiliation: Department of Genetics, Istituto di Ricerche di Biologia Moleculare, Rome, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Toniatti
authors.forename: A
authors.initials: A
authors.lastname: Cabibbo
authors.forename: E
authors.initials: E
authors.lastname: Sporena
authors.forename: A L
authors.initials: AL
authors.lastname: Salvati
authors.forename: M
authors.initials: M
authors.lastname: Cerretani
authors.forename: S
authors.initials: S
authors.lastname: Serafini
authors.forename: A
authors.initials: A
authors.lastname: Lahm
authors.forename: R
authors.initials: R
authors.lastname: Cortese
authors.forename: G
authors.initials: G
authors.lastname: Ciliberto
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D017104:Bacteriophage M13 / Q000235:genetics; D001483:Base Sequence; D050822:Cytokine Receptor gp130; D017931:DNA Primers / Q000737:chemistry; D015723:Gene Library; D005818:Genetic Engineering; D005822:Genetic Vectors; D006801:Humans; D015850:Interleukin-6 / Q000737:chemistry* / Q000235:genetics; D008562:Membrane Glycoproteins / Q000378:metabolism; D008958:Models, Molecular; D008969:Molecular Sequence Data; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D018123:Receptors, Interleukin / Q000378:metabolism; D019947:Receptors, Interleukin-6; D013329:Structure-Activity Relationship
chemical_list: D015703:Antigens, CD; D017931:DNA Primers; C494199:IL6ST protein, human; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D018123:Receptors, Interleukin; D019947:Receptors, Interleukin-6; D050822:Cytokine Receptor gp130